Skip to content

Geron GERN Current ratio

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.4×+0.1×
Incyte logo
IncyteINCY
3.7×+1.6×
Immunome logo
ImmunomeIMNM
21.7×+11.2×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
5.5×-0.3×
Arcus Biosciences logo
Arcus BiosciencesRCUS
-1.3×
Celcuity logo
CelcuityCELC
12.3×+5.7×

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-7.6%
Enterprise value$973.78M-5.3%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×

Where this comes from

Calculated from Geron’s reported figures.

Based on the most recent quarter.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's current ratio?
Geron (GERN) reported current ratio of 6.8× in Q1 2026.
How has Geron's current ratio changed year-over-year?
Geron's current ratio decreased by 13.8% year-over-year, from 7.9× to 6.8×.
What is the long-term trend for Geron's current ratio?
Over 5 years (2020 to 2025), Geron's current ratio has grown at a -6.3% compound annual growth rate (CAGR), from 6.5× to 4.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.